<u>Cuore</u> <u>e</u> <u>cervello</u>: <u>dalla trombolisi</u> alle <u>procedure interventistiche</u>.

Analogie e differenze di due percorsi clinici e scientifici.

Mauro Gallitelli

Ospedale «Santi Giovanni e Paolo» - Venezia



















Thrombolytics in Stroke **DEBATE**







Figure I Catheter-based thrombectomy in acute anterior stroke. (A) Middle cerebral artery occlusion (arrow) at presentation, (B) positioning of the stent-retriever (arrow point to the occlusion site), (C) final result after thrombectomy (arrow points to the previously occluded site; note the absence of any underlying stenosis after thrombus extraction), (D) fragmented thrombus and the retriever. Patient neurological status normalized.

Interventional Management of Stroke III (IMS III)



N Engl J Med. 2013;368:914-23.

1. Pochi pazienti trattati con stent retrievers



2. Disegno dei trials (selezione dei pazienti)

IMS III, Synthesis Expansion

No Angio-TC o Angio-RM

MR RESCUE

Arruolamento di pazienti con un grosso core infartuale

3. Tempi da inizio di trombolisi ev a trattamento endovascolare molto lunghi

IMS III

Endovascular treatment of acute ischemic stroke: the end or just the beginning?

MAXIM MOKIN, M.D., PH.D.,¹ ALEXANDER A. KHALESSI, M.D., M.S.,³ J MOCCO, M.D., M.S.,⁴ GIUSEPPE LANZINO, M.D.,⁵ TRAVIS M. DUMONT, M.D.,¹ RICARDO A. HANEL, M.D., PH.D.,⁶ DEMETRIUS K. LOPES, M.D.,⁷ RICHARD D. FESSLER II, M.D.,⁸ ANDREW J. RINGER, M.D.,⁹ BERNARD R. BENDOK, M.D.,¹⁰ EROL VEZNEDAROGLU, M.D.,¹¹ ADNAN H. SIDDIQUI, M.D., PH.D.,^{1,2} L. NELSON HOPKINS, M.D.,^{1,2} AND ELAD I. LEVY, M.D., M.B.A.^{1,2}

Departments of ¹Neurosurgery and ²Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York; ³Division of Neurosurgery, University of California, San Diego, California; ⁴Department of Neurosurgery, Vanderbilt University, Nashville, Tennessee; ⁵Departments of Neurologic Surgery and Radiology, Mayo Clinic, Rochester, Minnesota; ⁶Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida; ⁷Department of Neurosurgery, Rush University Medical Center, Chicago, Illinois; ⁸Department of Neurosurgery, St. John Providence Health System, Detroit, Michigan; ⁹Department of Neurosurgery, Mayfield Clinic, University of Cincinnati, Ohio; ¹⁰Department of Neurosurgery, Northwestern University, Chicago, Illinois; and ¹¹Department of Neurosurgery, Capital Health Institute for Neurosciences, Trenton, New Jersey



MR CLEAN

HA.Marqueing.MES. W.H. Jan Zuom, Y.B.W.EM. I

EXTEND-IA

SWIFT PRIME

e when eligible)

REVASCAT

Thrombectomy within & Hours after

bolo na k on nigoni sa holini k bola M. Ribe M. hallen X. no olini k constant a sa holini X. bola da holini X. bola da holini k

is for the REVASCAT Trial

my for the

ified Rankin scale

Symptom Onset in Ischemic Stroke

1.C. Jovin A. Channors L. San Roman J. Semanning S. San Roman J. Semannis S. San Roman J. Semannis S. Abblens H. Ouesade M. Rubiers M. Abblens M. Horsello J. T.G. Jovin, A. Cham

^H, Quesada M, Rublera M, Hernandez, ^C von Kummer, M, Gallofel and A, Dénandez, Dénalog

- We alried to assess the safety and efficacy of thromber stroke is a trial embedded within a bepulation-based set We direct to assess the sates and entrates - stroke in a trait embedded within a populati

t-PA VS. t-PA Alone in Strok

Jeffrey L. Saver, M.D., Mayank Goyal, M.D., Alain Bor Christoph Diener, M.D., ph. D., Flad I, Jawa M.D., Alain Bor Vice of the state of

ESCAPE

ORIGINAL ARTICLE

ORIGINAL ARTICLE Randomized Assessment of Endovascular Treatment of Isch

The NEW ENGLAM M. Goyal, A.M. Demchuk, B.K. Menon, M. Eesa, J.L. Remp M. Goyai, A.M. Demcnus, D.A. Menori, M. Cesa, J.L. Reniy T.G. Jovin, R.A. Willinsky, B.L. Sapkota, D. Dowlatshahi, W.J. Montanera, A.Y. Poppe, K.J. Ryckborst, F.L. Silver, A JOURNAL of MED " D. Williams, O. t. bang, D.W. baxer, P.A. burns, H CA. Holmstedt, B. Jankowitz, M. Kelly, G. Linares, J.L C.A. Fromstear, D. Jankownz, M. Kelly, G. Linares, J.L. S.J. Sohn, R.H. Swartz, P.A. Barber, S.B. Coutts, E.E. A. Weill, S. Subramaniam, A.P. Mitha, J.H. Wong T.T. Sajobi, and M.D. Hill for the ESCAPE Tria

Stent-Retriever Thrombectomy after Ir Endovascular Therapy for Ischer with Perfusion-Imaging Se

K. Steinford, M. Priglinger, T. Ang, R. Scroop, P. J. Margar, M. S. Man, M. D. M. Standar, M. Standar, S. Steinford, M. M. Strauser, T.J. 'Hear Hacke, M. M. M. D. M. Standar, M. M. Standar, Standar, Standar, M. Standar, Standar, Standar, M. Standar, Standar, M. Standar, M. Hans-christoph Diener, M.D., Mayank Goyal, M.D., Alain Bor Greeory W. Albers, M.D., Ph.D., Elad. I. Levy, M.D., Vito M.D., Christophe Cognant, M.D., Davi .C.V. Campbell, P.J. MITCHALL, B. Yan, R.J. Dowling, M.W. Parsons, 1., M.A. Simpson, F. Miteff, C.R. Levi, M. Krause, T.J. <u>Hennich, Phattie</u>, M.D. <u>Andrews, Christopherova</u>, I. Lev, A. B.S. Steinfort, M. Priglinger, T. Ang, R. Scroop, P.J. <u>Dillego R. Mattie</u>, M.D. <u>Andrews, Christopherova</u>, I. Lev, B.S. Steinfort, M. Priglinger, T. Ang, R. Scroop, P.J. <u>Dillego R. M.D. Mattie</u>, M.D. <u>Andrews, Christopherova</u>, I. Lev, B.S. Steinfort, M. Priglinger, T. Ang, R. Scroop, P.J. <u>Dillego R. M.D. Mattie</u>, M.D. <u>Andrews, M.D. Christopherova</u>, J. Lev, B.S. Steinfort, M. Priglinger, T. Ang, R. Scroop, P.J. <u>Dillego R. M.D. Mattie</u>, M.D. <u>Andrews, M.D. Mattie</u>, M.D. <u>Andrews</u>, M.D. <u>Andr</u> Hans-Christoph Diener, M.D., Ph.D., Elad J. Levy, M.D., Vito Gregory W. Alberg, M.D., Christophe Cognard, M.D., Vito Heinrich, P., Mattle, M.D., Raul, G. Nogueira, M.D., Ph.D., Tur, R. Raul, G. Nogueira, M.D., Adnan H., Y. . Yan, K.J. C. . Simpson, F. Miteff, L.K.L. . Steinfort, M. Priglinger, T. Ang, R. Succ. jeratne, T.G. Phan, W. Chong, R.V. Chandra, *Clognetics & Logest M.D.*, *Islais W. Batter, M.D.*, *Adnas M.D.*, *Islais W. Batter, M.D.*, *Adnas M.D.*, *Better, M.D.*, *Adnas M.D.*, *Adnas M.D.*, *Better, M.D.*, *Better, M.D.*, *Adnas M.D.*, *Better, M.D.*, *Better, M.D.*, *Adnas M.D.*, *Better, M.D.*, *Bette* Jovin, R.A., Y. Poppe, K.J. Ryckborst, F.L. Sawer, B.S. Steinfort, M. Priglinger, T. Ang, R. Scroop, P./ Di Montanera, A.Y. Poppe, K.J. Ryckborst, F.L. Sawer, H. T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.D. D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.D. D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.D. D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.D. D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.D. D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.D. D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.D. D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.D. D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.D. D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. Ma, P.M. Desmond, C.A. F.

ALCERCOUND Trials of endorascular therapy for ischemi trace and interventis with actue ischemic stroke due to occurs interventision rates and or a stem tetricer, in addition to interventision frates and may improve long-term functional for the view of actual discussion to interventise for interventions to interve long-term functional interventions of the based of the A Randomized Trial of Intranterial

 ABSTRACT
 EXCREMUND

 Trials of endowascular therapy for ischemic reaction intraction intraction intraction intraction intraction intraction intraction intraction intraction interaction interac Trials of encourse Trials

nong patients with a proximal vessel occlusion. fatients die within 90 days after stroke onset or do t fatients die within 90 days after stroke onset or do t denee despite alrephase treatment. We evaluated rapid et **METHODS** into us standard care in patients with acute ischemic st? We randomly assigned patients with <u>we randomly assigned patients</u> assigned patients with <u>we randomly assigned patients</u> and <u>we randomly assigned patients</u> and <u>we randomly assigned patients</u> assigned <u>patients</u> assigned <u>patients</u> assigned <u>patients</u> and <u>moderate</u> alrephase treatment. We evaluated rapid et <u>alrephase</u> treatment we randomly assigned patients with acute ischemic st? proximal intracranial arterial occlusion, and moderate alrephase patients had occlusion of the intragarphore on save functional with a stroke either to undergo on the intragarphore on save functional with with stroke with stroke with stroke with stroke with stroke with with stroke nes die witzu-ens die witzu-diespite alteplae treatme. to stadard care in patients wih aus. simal intracranial atterial occlusion, and mou-simal intracranial atterial occlusion, and mou-simal intracranial atterial occlusion, and mou-simal intracranial atterial occlusion. THOOS We radionly assigned participants or receive standard vention group). Patients with a proximal intracranial vention group). Patients with a proximal intracranial state plus advosculat reatment with the use of and or poor collateral circulation on computed com interview interview

implifier inported inport doo. do a 90 don-do a 90 do by 6 by The trial was stopped early because of efficacy. I group than in the al₀-¹²th the by 6 by The trial was stopped early because of efficacy. I group that in the al₀-¹²th the by 12 by 1 Sectors
For trial was support easi, and the sector of the sect The results of the first repetition of finite repetition of functional out the results of the first repetition of the first repetition of functional out of the repetition of the first repetition o



	Recanalization			n at 90 ays	Independence (mRS 0-2) at 90 days		
	MT	Control	MT	Control	MT	Control	
MR CLEAN ¹	75%	32%	21%	22%	33%	19%	
ESCAPE ²	72%	31%	10%	19%	53%	29%	
EXTEND IA ³	100%	37%	9%	20%	71%	40%	
SWIFT PRIME ⁴	83%	40%	9%	12%	60%	36%	
REVASCAT ⁵	66%	-	18%	15%	44%	28%	
TOTAL ⁶	71%	-	15%	19%	46%	27%	

1. Berkhmeer et al. NEJM 2015

4. Saver et al. NEJM 2015

5. Jovin et al. NEJM 2015

2. Goyal et al. NEJM 2015

- . . .

3. Campbell et al. NEJM 2015

6. Goyal et al. Lancet 2016





...ruolo della Trombolisi...

CONS

Ineffective in the majority of LVO stroke

Increases the risks of sICH

Can delay MT

Can soften the thrombus and cause distal embolization (where MT not possible)

Is a contraindication for heparin and antiplatelets (which can be useful in MT)

TL can increase costs w/o advantages

PROS

Can recanalize some vessels

Can be started earlier than MT

Can soften the thrombus (less catheter passages) Can help with distal embolization during MT

Endovascular Thrombectomy Alone versus Combined with Intravenous Thrombolysis

Kevin Phan¹, Adam A. Dmytriw², Julian Maingard^{3,4}, Hamed Asadi³⁻⁵, Christoph J. Griessenauer², Wyatt Ng¹, Kitso Kewagamang¹, Ralph J. Mobbs¹, Justin M. Moore², Christopher S. Ogilvy², Ajith J. Thomas²

BACKGROUND: To date, no randomized trial has directly addressed the question of whether intravenous (IV) tissue plasminogen activator (tPA) improves outcomes in IV tPAeligible patients who will eventually undergo endovascular therapy (EVT), or whether a direct EVT strategy is equally effective. We performed a systematic review and meta-analysis to compare the efficacy and safety of direct EVT versus endovascular treatment with IV tPA (EVT + IV tPA) in adults with acute ischemic stroke.

METHODS: We performed electronic searches of 6 databases from their inception to January 2017. Data were extracted and analyzed according to predefined clinical endpoints.

■ RESULTS: Twelve comparative studies, comprising 1275 patients in the EVT-only arm and 1340 patients in the combined EVT + IV tPA arm, were included. The rates of good functional outcomes (modified Rankin Scale score \leq 2) and 90-day mortality were not statistically significantly different between the EVT and EVT + IV tPA arms (44% vs. 48%; odds ratio [OR], 0.80; 95% confidence interval [CI], 0.64-1.002; P = 0.052 and 20.4% vs. 19.4%, OR 1.19; 95% CI, 0.83-1.71; P = 0.34, respectively). The rate of symptomatic intracranial hemorrhage also was not significantly different between the EVT and EVT + IV tPA arms (3.7% vs. 3.8%; OR, 0.98; 95% CI, 0.65-1.48; P = 0.91). There were no between-group differences in the rates of other complications.

CONCLUSIONS: No significant differences between the 2 groups were found in terms of favorable functional outcome, mortality rate, or complications based on contemporary endovascular therapies.

INTRODUCTION

umerous studies have demonstrated the benefits of intravenous (IV) tissue plasminogen activator (tPA) for treating acute ischemic stroke, regardless of stroke subtype.¹ The aim of IV tPA therapy is to recanalize the affected blood vessel and establish reperfusion.² However, in large vessel occlusions, the efficacy of reperfusion using IV tPA alone has been suboptimal, with recanalization rates as low as 6% for occlusion of the terminal internal carotid artery.³⁴

Recently, the publication of multiple randomized controlled trials⁵⁻⁸ convincingly demonstrated that the addition of endovascular thrombectomy (EVT) to IV tPA improved outcomes after acute ischemic stroke caused by large vessel occlusions. The design of these trials was such that the majority of patients who were treated with mechanical thrombectomy also received IV thrombolysis. However, the number of patients in these trials who did not receive previous IV tPA was very small, and thus whether

	EVT		EVT+IVT			Odds Ratio	Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Rand	lom, 95% Cl	
Publications befor	e 2015									
Bhatia et al 2014	23	53	46	104	8.4%	0.97 [0.50, 1.88]				
Davalos et al 2012	28	67	49	74	8.1%	0.37 [0.18, 0.73]	←			
Kass-Hout et al 2014	20	58	15	40	5.9%	0.88 [0.38, 2.03]			·	
Pfefferkron et al 2012	3	23	11	26	2.2%	0.20 [0.05, 0.86]	+-			
Sallustio et al 2013 Subtotal (95% CI)	12	30 231	7	16 260	3.0% 27.7%	0.86 [0.25, 2.93] 0.61 [0.36, 1.04]		-		
Total events	86		128							
Heterogeneity: Tau ² = 0.16	; Chi ² = 7.	18, df =	4 (P = 0	.13); I ²	= 44%					
Test for overall effect: Z =				,,						
Publications in 201	15 and aft	er								
Abeillera et al 2017	271	599	267	567	24.9%	0.93 [0.74, 1.17]			-	
Broeg-Morvay et al 2016	17	40	71	156	7.8%	0.88 [0.44, 1.78]				
Coutinho et al 2017	61	128	90	156	13.6%	0.67 [0.42, 1.07]			+	
Guedin et al 2015	21	40	19	28	4.3%	0.52 [0.19, 1.43]			-	
eker et al 2015.	17	33	10	24	3.9%	1.49 [0.52, 4.30]				
Rai et al 2017	26	52	22	38	5.8%	0.73 [0.31, 1.69]				
Weber et al 2015	58	145	37	105	12.0%	1.23 [0.73, 2.06]				
Subtotal (95% CI)		1037		1074	72.3%	0.90 [0.75, 1.07]			▶	
Total events	471		516							
leterogeneity: Tau ² = 0.00	; Chi ² = 5.	19, df =	6 (P = 0	.52); I ²	= 0%					
Test for overall effect: Z =	1.19 (P = ().23)								
Total (95% CI)		1268		1334	100.0%	0.80 [0.64, 1.00]		•		
Total events	557		644							
leterogeneity: Tau ² = 0.04 est for overall effect: Z =	A CONTRACTOR OF A CONTRACT OF		= 11 (P =	= 0.17);	l² = 28%		0.2	0.5 Favours EVT+IVT	1 2 Favours EVT	
Fest for subgroup difference	es: Chi ² =	1.83. c	f = 1 (P =	0.18).	12 = 45.2%	6				

Figure 2. Forest plot of the odds ratio (OR) of 90-day favorable functional outcome (modified Rankin Scale score ≤2) for endovascular therapy (EVT) versus endovascular therapy and intravenous tissue plasminogen activator



An American Heart Association Journal An American Heart Association 2017 Sep 24. pii: CIRCULATIONAHA.117.028920. doi: 10.1161/CIRCULATIONAHA.117.028920. [Epub ahead of print]

Interhospital Transfer Prior to Thrombectomy is Associated with Delayed Treatment and Worse Outcome in the STRATIS Registry.

Froehler MT¹, Saver JL², Zaidat OO³, Jahan R², Aziz-Sultan MA⁴, Klucznick RP⁶, Haussen DC⁶, Hellinger FR Jr⁷, Yavagal DR⁸, Yao TL⁹, Liebeskind DS², Jadhav AP¹⁰, Gupta R¹¹, Hassan AE¹², Martin CO¹³, Bozorgchami H¹⁴, Kaushal R¹⁵, Nogueira RG⁶, Gandhi RH⁷, Peterson EC⁶, Dashti SR⁹, Given CA 2nd¹⁶, Mehta BE¹⁷, Deshmukh V¹⁸, Starkman S², Linfante I¹⁹, McPherson SH²⁰, Kvamme P²¹, Grobelny TJ²², Hussain MS²³, Thacker I²⁴, Vora N²⁶, Chen PR²⁸, Monteith SJ²⁷, Ecker RD²⁸, Schirmer CM²⁹, Sauvageau E³⁰, Abou-Chebl A³¹, Derdeyn CP³², Maidan L³³, Badruddin A³⁴, Siddiqui AH³⁵, Dumont TM³⁶, Alhajeri A³⁷, Taqi MA³⁸, Asi K³⁹, Carpenter JS⁴⁰, Boulos A⁴¹, Jindal G⁴², Puri AS⁴³, Chitale R⁴⁴, Deshaies EM⁴⁵, Robinson DH⁴⁶, Kallmes DF⁴⁷, Baxter BW⁴⁸, Jumaa MA⁴⁹, Sunenshine P⁶⁰, Majjhoo AQ⁵¹, English JD⁶², Suzuki S⁶³, Fessler RD⁵⁴, Delgado Almandoz JE⁵⁵, Martin JC⁶⁶, Mueller-Kronast NH¹⁵; STRATIS Investigators.

Author information

Abstract

Background -Endovascular treatment with mechanical thrombectomy (MT) is beneficial for acute stroke patients suffering a large vessel occlusion, though treatment efficacy is highly time-dependent. We hypothesized that interhospital transfer to endovascular-capable centers would result in treatment delays and worse clinical outcomes compared to direct presentation. Methods -STRATIS was a prospective, multicenter, observational, single-arm study of real-world MT for acute stroke due to anterior-circulation large vessel occlusion performed at 55 sites over 2 years, including 1000 patients with severe stroke and treated within 8 hours. Patients underwent MT with or without IV-tPA, and were admitted to endovascular-capable centers via either interhospital transfer or direct presentation. The primary clinical outcome was functional independence (modified Rankin Score 0-2) at 90 days. We assessed 1) real-world time metrics of stroke care delivery, 2) outcome differences between direct and transfer patients undergoing MT, and 3) the potential impact of local hospital bypass. Results -A total of 984 patients were analyzed. Median onset-to-revascularization time was 202.0 minutes for direct vs. 311.5 minutes for transfer patients (p<0.001). Clinical outcomes were better in the direct group with 60.0% (299/498) achieving functional independence, compared to 52.2% (213/408) in the transfer group (odds ratio 1.38, 95%CI 1.06-1.79; p=0.02). Likewise, excellent outcome (modified Rankin Score 0-1) was achieved in 47.4% (238/498) of direct patients vs. 38.0% (155/408) of transfer patients (odds ratio 1.47, 95%CI 1.13-1.92; p=0.005). Mortality did not differ between the two groups (15.1% for direct. 13.7% for transfer; p=0.55). IV-tPA did not impact outcomes. Hypothetical bypass modeling for all transferred patients suggested that IV-tPA would be delayed by 12 minutes but MT would be performed 91 minutes sooner if patients were routed directly to endovascular-capable centers. If bypass is limited to a 20-mile radius from onset, then IV-tPA would be delayed by 7 minutes and MT performed 94 minutes earlier. Conclusions -In this large, real-world study, interhospital transfer was associated with significant treatment delays and lower chance of good outcome. Strategies to facilitate more rapid identification of large vessel occlusion and direct routing to endovascular-capable centers for severe stroke patients may improve outcomes. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique identifier: NCT02239840.

Guideline

Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13–15 November 2016

Niaz Ahmed^{1,2}, Thorsten Steiner^{3,4}, Valeria Caso⁵ and Nils Wahlgren²; for the ESO-KSU session participants* EUROPEAN STRUKE JOURNAL European Stroke Journal (0) 1–8 © European Stroke Organisation 2017 Reprints and permissions: sagepub co.uk/journals/Permissions.nav DOE 10.1177/2396987317699144 journals.sagepub.com/home/eso

Session 10: Prehospital triage for mechanical thrombectomy

B. Mechanical thrombectomy: 'Drip and ship' or 'load and go'?

- 3. For patients with a suspected LAO based on current clinical tools on field, there is uncertainty about the equipoise between drip and ship (that prioritizes early IVT and other standard of care therapies) and mother-ship (that prioritizes early endovascular thrombectomy) models. Data based on randomized controlled trials are needed to determine the most beneficial model for each particular patient (eligible or not for iv-tPA) in different geographical regions and to establish isochrones where a particular model may be beneficial (Grade C).
- 4. In the absence of evidence, for patients considered eligible to IVT in the field, if estimated transfer time to the nearest primary stroke centre is considerably shorter than time to a comprehensive stroke centre (approximately more than 30–45 min), the drip and ship model should be considered (Grade C).
- 5. In the absence of evidence, in a scenario where a primary stroke centre and comprehensive stroke centre are equidistant (approximately not more than 30–45 min apart) or when contraindications to IVT are known in the field, patients with suspected LAO in the field, should be considered for transfer directly to a comprehensive stroke centre, bypassing any closer primary stroke centres (Grade C).
- 6. In case of primary admission to a primary stroke centre, evaluation and treatment for patients with a possible LAO must be expeditious, to ensure a rapid secondary transfer to a comprehensive stroke centre, avoiding any sources of delay such as complex neuroimaging studies (i.e. perfusion studies) or waiting for effect of IVT. First picture to puncture time should be less than 90 min (Grade A).

J Neurointerv Surg. 2017 Mar;9(3):229-233. doi: 10.1136/neurintsurg-2015-012236. Epub 2016 Feb 22.

Comparison of outcome and interventional complication rate in patients with acute stroke treated with mechanical thrombectomy with and without bridging thrombolysis.

Weber R¹, Nordmeyer H², Hadisurya J¹, Heddier M², Stauder M², Stracke P², Berger K³, Chapot R².

Author information

- 1 Department of Neurology, Alfried Krupp Krankenhaus Essen, Essen, Germany.
- 2 Department of Radiology and Neuroradiology, Alfried Krupp Krankenhaus Essen, Essen, Germany.
- 3 Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.

Abstract

BACKGROUND: No randomized trial has investigated the effect of mechanical thrombectomy (MT) alone in patients with acute stroke. There are conflicting results as to whether prior intravenous thrombolysis (IVT) facilitates subsequent MT, and data in patients treated with MT alone owing to contraindications to IVT are limited.

OBJECTIVE: To compare consecutive patients treated with MT alone or with preceding IVT in a large tertiary neurointerventional center, with special emphasis on contraindications to IVT.

METHODS: Retrospective analysis of 283 consecutive patients with acute ischemic stroke treated with MT in a tertiary neurovascular center over 14 months. Data on characteristics of periprocedural times, recanalization rate, complications, and long-term functional outcome were collected prospectively.

RESULTS: Information on prior IVT and functional outcome was available in 250 patients. Mean (SD) follow-up period was 5.7 (5.1) months and 105 (42%) patients received both IVT and MT. No significant differences were found in successful recanalization rates (Thrombolysis in Cerebral Infarction (TICI) 2b/3, 73.8% vs 73.1, p=0.952), complication rates, and long-term favorable outcome (modified Rankin Scale 0-2, 35.2% vs 40%, p=0.444) between patients receiving MT plus IVT and those receiving MT alone. A favorable outcome in patients directly treated with MT alone who were eligible for IVT was achieved in 48.2%. Thrombectomy was safe and resulted in a favorable outcome in 32% of patients with absolute contraindications to IVT.

CONCLUSIONS: Preceding use of IVT was not an independent predictor of favorable outcome in patients with acute stroke treated with MT and complication rates did not differ whether or not IVT was used. MT is safe and achieved a favorable outcome in one-third of patients with stroke ineligible for IVT.

Direct Mechanical Intervention Versus Combined Intravenous and Mechanical Intervention in Large Artery Anterior Circulation Stroke

A Matched-Pairs Analysis

Anne Broeg-Morvay, MD*; Pasquale Mordasini, MD, MSc*; Corrado Bernasconi, MD, PhD; Monika Bühlmann, MD; Frauke Pult, MD; Marcel Arnold, MD; Gerhard Schroth, MD; Simon Jung, MD; Heinrich P. Mattle, MD; Jan Gralla, MD, MSc*; Urs Fischer, MD, MSc*

Background and Purpose—Five randomized controlled trials have consistently shown that mechanical thrombectomy (MT) in addition to best medical treatment (±intravenous tissue-type plasminogen activator) improves outcome after acute ischemic stroke in patients with large artery anterior circulation stroke. Whether direct MT is equally effective as combined intravenous thrombolysis with MT (ie, bridging thrombolysis) remains unclear.

- Methods—We retrospectively compared clinical and radiological outcomes in 167 bridging patients with 255 patients receiving direct MT because of large artery anterior circulation stroke. We matched all patients from the direct MT group who would have qualified for intravenous tissue-type plasminogen activator with controls from the bridging group, using multivariate and propensity score analyses. Functional independence was defined as modified Rankin Scale score of 0 to 2.
- Results—From February 2009 to August 2014, 40 patients from the direct MT group would have qualified for bridging thrombolysis but were treated with MT only. Clinical and radiological characteristics did not differ from the bridging cohort, except for higher rates of hypercholesterolemia (P=0.019), coronary heart disease (P=0.039), and shorter intervals from symptom onset to endovascular intervention (P=0.01) in the direct MT group. Functional independence, mortality, and intracerebral hemorrhage rates did not differ (P>0.1). After multivariate matching analysis outcome in both groups did not differ, except for lower rates of asymptomatic intracerebral hemorrhage (P=0.023) and lower mortality (P=0.007) in the direct MT group.

Conclusions—In patients with large anterior circulation stroke, direct mechanical intervention seems to be equally effective as bridging thrombolysis. A randomized trial comparing direct MT with bridging therapy is warranted. (Stroke, 2016;47:1037-1044. DOI: 10.1161/STROKEAHA.115.011134.)

Home » The SWIFT DIRECT trial

The SWIFT DIRECT trial

Solitaire[™] With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire[™] Stentretriever Thrombectomy in Acute Anterior Circulation Stroke (SWIFT DIRECT).

Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke.

Please find more information on www.clinicaltrials.gov





Diagnosi più complessa (Tecnologia necessaria, Capacità di Interpretazione)

Finestra terapeutica più ristretta

Anatomia del circolo cerebrale (Vasi piccoli, tortuosi, variabilità anatomica)

Danno da riperfusione (emorragia cerebrale)

Assente evidenza di farmaci utili nel peri-procedurale

Approccio multidisciplinare

Basso numero di pazienti trattati (curve di apprendimento)



...semplice













CENTRALIZZAZIONE

DEL

PAZIENTE



Acta Neurol Scand. 2018 Feb 11. doi: 10.1111/ane.12908. [Epub ahead of print]

Prehospital stroke scales and large vessel occlusion: A systematic review.

Vidale S1, Agostoni E1.2.

- Author information
- 1 Department of Neurology & Stroke Unit, Sant'Anna Hospital, Como, Italy.
- 2 Department of Neurology & Stroke Unit, Niguarda Ca' Granda Hospital, Milan, Italy.

Abstract

BACKGROUND AND PURPOSE: Time sensitivity for pharmacological and mechanical arterial recanalization in acute ischemic stroke influences the choice of the reference hospital. The accurate selection and identification of patients with high probability of a large vessel occlusion (LVO) in the prehospital setting improve the rationalization of the transport in the more suitable centers. Aim of this analysis was to determine the diagnostic accuracy of prehospital stroke scales detecting LVO.

MATERIAL AND METHODS: Studies were searched into MEDLINE, EMBASE, and CINHAL databases between January 1990 and September 2017. Principal measurements of the meta-analysis were the overall accuracy level, sensitivity, and specificity of prehospital stroke scales.

RESULTS: Nineteen scoring systems were included in the analysis coming from 13 studies. A total of 9824 patients were considered. Although a higher heterogeneity was observed in the analysis, three scores showed better results in predicting a LVO (the stroke Vision, Aphasia, Neglect assessment, the National Institute of Health Stroke scale and the Los Angeles Motor Scale). We observed significant differences of overall accuracy only for scores including hemineglect as cortical neurological sign (P < .05).

CONCLUSIONS: This meta-analysis suggests that some prehospital scoring systems including cortical signs showed better accuracy to predict stroke due to LVO. However, the assessment of these signs could be difficult to investigate by paramedics and personnel of Emergency Medical Services, and for this reason, further prospective evaluations are needed.









Sensitivity/Specificity



Guideline

Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13–15 November 2016

EUROPEAN Stroke Journal

European Stroke Journal 0(0) 1–8 © European Stroke Organisation 2017 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2396987317699144 journals.sagepub.com/home/eso



Session 10: Prehospital triage for mechanical thrombectomy

Chair: U. Fischer (Bern), Secretary: M. Mazya (Stockholm), Speakers: D. Damgaard (Aarhus), A. Davalos (Barcelona), M. Mazya (Stockholm)

A. Clinical identification of stroke patients with large vessel occlusion: Current evidence and limitations

- Several published clinical scores to predict large artery occlusion (LAO) appear to have similar predictive performance in the range of 70-80%, resulting in 20-30% of patients with LAO being missed at optimal score cut-off levels. At the same cut-off levels, 12-25% of triage positive patients would not have a LAO (Grade C).
- Studies validating the predictive performance of currently available LAO prediction scores should be performed in pre-hospital settings in unselected patients with a suspicion of stroke following initial contact with emergency medical services (Grade C).

Mobile Stroke Units...




...ampia









NINDS

3 hours

ECASS III

4.5 hours

MR CLEAN ESCAPE EXTEND – IA SWIFT-PRIME REVASCAT

6 hours



Novembre 2017

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE



Gennaio 2018

Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging



Imaging avanzato (TC di perfusione o DW-MRI)



«Last time seen well»

Interquartile range	2.0-18.0	3.0-18.1
pe of stroke onset — no. (%)‡		
On awakening	67 (63)	47 (47)
Unwitnessed stroke	29 (27)	38 (38)
Witnessed stroke	11 (10)	14 (14)

(Dawn trial, 2017)

Solo il 5% dei pazienti con

stroke riceve un trattamento riperfusivo

Hirsch JA, Yoo AJ, Noguiera RG et Al. Case volumes of intra-arterial and intravenous treatment of ischemic stroke in the USA. J Neurointerv Surg 2009;1:27–31.



Entrambi tempo - dipendenti ma fattore tempo è critico per lo **STROKE**





The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke

Petr Widimsky¹*, Wolfram Doehner^{2,3}, Hans Christoph Diener⁴, Isabelle C. Van Gelder⁵, Alison Halliday⁶, and Mikael Mazighi⁷ on behalf of the ESC Council on Stroke

Endovascular treatment and catheterbased thrombectomy

The recent advances in interventional treatment of acute stroke^{32–36} established catheter-based thrombectomy (on top of best medical therapy) as class IA indication for the treatment of anterior circulation stroke (*Figure 3*) caused by emergent large vessel occlusion presenting within <6 h from symptom onset^{37,38} The DAWN trial (presented during ESOC 2017, publication pending) showed that with the use of sophisticated magnetic resonance imaging, the therapeutic time window can be extended to 24 h. Currently, over 10% of stroke patients are eligible for endovascular treatment but future

research and clinical experience will have to prove the full potential of this treatment.

A number of questions emerged from the recent trials that will be addressed in future studies: those include questions on logistics and timing as well as procedural issues, patient selection, concomitant treatments and others. One multisociety consensus document proposed general standards for hospital requirements and physician qualifications for performing endovascular stroke interventions.³⁹ The authors recognize that the implementation of such standards need to account for a wide variety of national clinical standards and procedural requirements. Further evaluation and interdisciplinary communication are needed to define on the basis of national and local requirements how physicians with related experience such as interventional cardiologists with carotid stenting (CAS) experience may be adequately trained for endovascular thrombectomy. Ongoing and future trials and interdisciplinary communication may answer these unresolved questions.⁴⁰





Manualità consolidata (PCI)

Esperienza con stenting della carotide

Grossi volumi di attività (Correlazione volumi – outcomes)

Network ben stabilito (Hub & Spoke dello STEMI)

Anatomia più difficile

(Vasi più piccoli, più tortuosi, con maggiore variabilità anatomica)

Tecniche differenti

Neuro-radiologi interventisti formatisi con esperienza da più patologie (Stroke ischemico, Aneurismi, Malformazioni vascolari)



Aspetti diagnostici

(Esame neurologico, Interpretazione TC, Angio-TC e TC di perfusione)

Aspetti procedurali



Trombectomia Meccanica UNICO trattamento???



I cardiologi interventisti... e la nicchia vuota???

